Lesinurad/allopurinol

Lesinurad/allopurinol is a combination medication used in the treatment of gout. It contains two active ingredients: lesinurad, which helps the kidneys to eliminate uric acid, and allopurinol, which reduces the production of uric acid in the body. This medication is used when allopurinol alone does not adequately control gout symptoms.

Indications

Lesinurad/allopurinol is indicated for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone.

Mechanism of Action

Lesinurad works by inhibiting the function of transporter proteins involved in uric acid reabsorption in the kidneys. This increases uric acid excretion and decreases serum uric acid levels. Allopurinol works by inhibiting xanthine oxidase, an enzyme involved in uric acid production. The combination of these two medications helps to control gout symptoms by both reducing the production of uric acid and increasing its excretion.

Side Effects

Common side effects of lesinurad/allopurinol include headache, influenza, increased blood creatinine, and gastroesophageal reflux disease. Serious side effects may include kidney failure, heart attacks, and strokes.

Contraindications

Lesinurad/allopurinol is contraindicated in patients with severe renal impairment, for whom the risks of the medication may outweigh the benefits. It is also contraindicated in patients undergoing dialysis and those with tumor lysis syndrome or Lesch-Nyhan syndrome.

Interactions

Lesinurad/allopurinol may interact with other medications, including azathioprine, mercaptopurine, and theophylline. Patients should inform their healthcare provider of all medications they are taking before starting treatment with lesinurad/allopurinol.

References

• FDA label for lesinurad/allopurinol. Accessed on 2021-09-15.
• MedlinePlus entry for lesinurad/allopurinol. Accessed on 2021-09-15.

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia